Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

OpenEvidence Secures $200M in Series C Funding, Valuation Soars to $6B

OpenEvidence Secures $200M in Series C Funding, Valuation Soars to $6B

OpenEvidence, a rapidly growing artificial intelligence startup in the medical field, has secured $200 million in Series C funding, propelling its valuation to $6 billion. This latest investment round comes just three months after the company's $210 million Series B, bringing its total funding to nearly $500 million since its founding in 2022.

NoahAI News10/21/2025
Highmark Partners with Noom to Offer Comprehensive Weight Management Solutions

Highmark Partners with Noom to Offer Comprehensive Weight Management Solutions

In a significant move to enhance member health services, Highmark has announced a partnership with digital health platform Noom to provide weight management solutions to its members. The collaboration, unveiled at the HLTH 2025 conference in Las Vegas, aims to offer personalized care journeys focusing on weight loss, diabetes prevention, and management.

NoahAI News10/21/2025
Grail's Galleri Cancer Blood Test Shows Promising Results, Eyes FDA Review

Grail's Galleri Cancer Blood Test Shows Promising Results, Eyes FDA Review

Grail, a biotechnology company focused on early cancer detection, has unveiled detailed data from its Pathfinder 2 study of the Galleri cancer blood test at the European Society for Medical Oncology (ESMO) 2025 conference in Berlin. The results demonstrate significant improvements in cancer detection rates and accuracy, paving the way for a potential FDA review.

NoahAI News10/21/2025
Merck's TROP2 ADC Shows Promise in Lung and Breast Cancer Trials

Merck's TROP2 ADC Shows Promise in Lung and Breast Cancer Trials

Merck & Co.'s ambitious development program for its TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) is gaining momentum, with the company's Chinese partner Kelun-Biotech reporting positive phase 3 results in lung and breast cancer at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin.

NoahAI News10/21/2025
AstraZeneca's In-House ADC Pipeline Shows Promise at ESMO

AstraZeneca's In-House ADC Pipeline Shows Promise at ESMO

AstraZeneca showcased promising data for its proprietary antibody-drug conjugate (ADC) pipeline at the European Society for Medical Oncology (ESMO) conference in Berlin, reinforcing the company's strategy to develop next-generation ADCs internally. The pharmaceutical giant presented results from a first-in-human study of AZD5335, a folate receptor α (FRα)-targeted ADC, demonstrating significant efficacy in platinum-resistant ovarian cancer patients.

NoahAI News10/19/2025
Tubulis' Next-Gen ADC Shows Promise in Early Clinical Trial, Justifying Recent $361M Investment

Tubulis' Next-Gen ADC Shows Promise in Early Clinical Trial, Justifying Recent $361M Investment

Tubulis, a German biotech company, has unveiled promising early clinical data for its next-generation antibody-drug conjugate (ADC) at the European Society for Medical Oncology (ESMO) congress in Berlin. The results, which mark the first in-human data for the therapy, appear to validate the recent substantial investment in the company.

NoahAI News10/19/2025
GSK's ADC Pipeline Shows Promise with Encouraging Data from Hansoh Partnership

GSK's ADC Pipeline Shows Promise with Encouraging Data from Hansoh Partnership

GSK's antibody-drug conjugate (ADC) pipeline is gaining momentum, with recent data presented at the European Society for Medical Oncology (ESMO) congress in Berlin showcasing promising results from two key assets developed in partnership with Chinese pharmaceutical company Hansoh.

NoahAI News10/19/2025
Novartis' Pluvicto Shows Promise in Hormone-Sensitive Prostate Cancer, Paving Way for FDA Application

Novartis' Pluvicto Shows Promise in Hormone-Sensitive Prostate Cancer, Paving Way for FDA Application

Novartis has unveiled detailed data from its phase 3 PSMAddition trial, demonstrating that its radioligand therapy Pluvicto could significantly slow the progression of certain hormone-sensitive prostate cancers. The results, presented at the 2025 European Society for Medical Oncology (ESMO) congress in Berlin, mark a potential expansion of Pluvicto's indications and patient population.

NoahAI News10/19/2025
Roche's Giredestrant Shows Promise in Advanced Breast Cancer Study

Roche's Giredestrant Shows Promise in Advanced Breast Cancer Study

Roche has unveiled promising results from a closely watched Phase 3 study of its experimental breast cancer drug giredestrant, potentially positioning the company to compete in the growing market for oral selective estrogen receptor degraders (SERDs).

NoahAI News10/19/2025
Akeso and Summit's Ivonescimab Shows Promise in First-Line NSCLC Treatment

Akeso and Summit's Ivonescimab Shows Promise in First-Line NSCLC Treatment

Akeso and Summit Therapeutics' novel bispecific antibody ivonescimab has demonstrated significant efficacy in delaying tumor progression compared to an established PD-1 inhibitor in combination with chemotherapy for first-line squamous non-small cell lung cancer (NSCLC) treatment. This breakthrough, presented at the 2025 European Society for Medical Oncology (ESMO) congress in Berlin, marks a potential shift in the landscape of cancer immunotherapy.

NoahAI News10/19/2025
Kite Pharma Leads Cell Therapy Push with $1.6B Pregene Deal Amid Industry Shifts

Kite Pharma Leads Cell Therapy Push with $1.6B Pregene Deal Amid Industry Shifts

Gilead Sciences' subsidiary Kite Pharma has inked a global licensing agreement worth up to $1.64 billion with Chinese biotech Pregene Biopharma, signaling a continued commitment to cell therapy development even as other pharmaceutical giants retreat from the field. The deal, which includes a $120 million upfront payment and up to $1.52 billion in milestone payments, focuses on advancing next-generation in vivo CAR-T therapies.

NoahAI News10/17/2025
Pharmaceutical Industry Faces Widespread Layoffs Amid Strategic Shifts

Pharmaceutical Industry Faces Widespread Layoffs Amid Strategic Shifts

The pharmaceutical and biotech sectors continue to grapple with a wave of layoffs and restructuring efforts as companies realign their priorities and respond to market pressures. From industry giants to smaller biotech firms, organizations across the board are making difficult decisions to streamline operations and focus on key programs.

NoahAI News10/17/2025
«1...181920...67»